SEC Tracker
Get the app

Cumberland Pharmaceuticals CPIX

Cumberland Pharmaceuticals reported Q3 2026 financial results

Cumberland Pharmaceuticals (CPIX) filed an 8-K with the SEC on Nov 10, 2026, 5:06 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Net income of $77.8 million for Q3 2026
  2. Cash and cash equivalents of $80.6 million as of September 30, 2026
  3. Plans to submit NDA for ifetroban in DMD

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Cumberland Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.